Polomar Health Services Inc
Polomar Health Services, Inc. (OTC: PMHS) is a Los Angeles, California-based healthcare services company that operates a retail compounding pharmacy at 10940 Wilshire Boulevard and provides prescription fulfillment services for third-party web-based telehealth platforms. The company was formed through the September 30, 2024 merger of Polomar Specialty Pharmacy, LLC into Trustfeed Corp., a company whose common stock was at that time quoted on the OTC Pink marketplace, creating the current Polomar Health Services Inc. corporate structure. Compounding pharmacies prepare customized medications tailored to individual patient needs when commercially available formulations are not suitable — due to allergies, required dosages, or alternative delivery methods — making them an important resource for patients whose medical needs cannot be adequately addressed by off-the-shelf pharmaceutical products.<br><br>The company owns and operates SlimRx, a weight loss-focused online telehealth platform that connects patients with licensed physicians who can prescribe compounded weight loss medications, including semaglutide combined with vitamin B-12 and/or metformin. The SlimRx platform participates in the rapidly expanding market for compounded GLP-1 receptor agonist medications, where semaglutide — the active ingredient in branded obesity and diabetes drugs — has seen extraordinary consumer demand driven by its clinical efficacy for weight loss, creating a significant compounded medication market. The company also intends to launch PoloMeds, a telehealth platform focused on diabetes medications including metformin compounds, sulfonylureas, and insulin, as well as compounded erectile dysfunction medications such as inhalable sildenafil.<br><br>Polomar Health Services, Inc. trades on the OTCID Basic Market under the ticker symbol PMHS and has filed a Form S-1 registration statement with the Securities and Exchange Commission, with subsequent S-1/A amendments reflecting the SEC's review process. The company employs a direct-to-consumer telehealth and compounding pharmacy model that integrates physician consultation, prescription, and medication fulfillment into a single digital platform experience, capitalizing on the intersection of the telehealth and compounding pharmacy industries. As regulatory and commercial dynamics around compounded GLP-1 medications continue to evolve — with FDA designation of drug shortage conditions affecting the legal framework for compounded semaglutide — Polomar Health Services participates in one of the most dynamic segments of the current healthcare and pharmaceutical market.